Summary
47.75 0.56(1.19%)09/27/2024
Merus N.V (MRUS)
Merus N.V (MRUS)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 1.36 | -3.65 | -9.92 | -20.65 | 6.49 | 98.22 | 104.07 | -33.58 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 47.75 | |
| Open | 47.50 | |
| High | 48.15 | |
| Low | 47.01 | |
| Volume | 288,171 | |
| Change | 0.64 | |
| Change % | 1.36 | |
| Avg Volume (20 Days) | 499,367 | |
| Volume/Avg Volume (20 Days) Ratio | 0.58 | |
| 52 Week Range | 19.81 - 61.48 | |
| Price vs 52 Week High | -22.33% | |
| Price vs 52 Week Low | 141.04% | |
| Range | 0.53 | |
| Gap Up/Down | -0.59 | |
Fundamentals | ||
| Market Capitalization (Mln) | 3,219 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 42.14 | |
| Book Value | 5.3300 | |
| Earnings Per Share | -2.2460 | |
| EPS Estimate Current Quarter | -0.6800 | |
| EPS Estimate Next Quarter | -0.6900 | |
| EPS Estimate Current Year | -1.9900 | |
| EPS Estimate Next Year | -2.9200 | |
| Diluted EPS (TTM) | -2.2460 | |
| Revenues | ||
| Profit Marging | -1.8510 | |
| Operating Marging (TTM) | -2.0643 | |
| Return on asset (TTM) | -0.1967 | |
| Return on equity (TTM) | -0.5537 | |
| Revenue TTM | 43,414,000 | |
| Revenue per share TTM | 1.2130 | |
| Quarterly Revenue Growth (YOY) | 0.5950 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -40,097,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 5.8999 | |
| Revenue Enterprise Value | 20.9246 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 42,671,600 | |
| Shares Float | 31,488,764 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 6.95 | |
| Institutions (%) | 57.90 | |
08/14 17:13 EST - seekingalpha.com
Merus: Great European Oncology Developer, But Properly Valued
Merus NV has seen a significant increase in market cap from $852mn to $3.46bn in the past year. Merus is a leader in developing multispecific antibodies with promising lead candidates petosemtamab and zenocutuzumab targeting various cancers. Merus has strong financials, and partnerships with major companies like Gilead, Incyte, and Eli Lilly, but faces risks due to its current valuation and assumptions about pipeline success.
Merus: Great European Oncology Developer, But Properly Valued
Merus NV has seen a significant increase in market cap from $852mn to $3.46bn in the past year. Merus is a leader in developing multispecific antibodies with promising lead candidates petosemtamab and zenocutuzumab targeting various cancers. Merus has strong financials, and partnerships with major companies like Gilead, Incyte, and Eli Lilly, but faces risks due to its current valuation and assumptions about pipeline success.
08/01 18:31 EST - zacks.com
Merus N.V. (MRUS) Reports Q2 Loss, Lags Revenue Estimates
Merus N.V. (MRUS) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.66 per share a year ago.
Merus N.V. (MRUS) Reports Q2 Loss, Lags Revenue Estimates
Merus N.V. (MRUS) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.66 per share a year ago.
08/01 16:10 EST - globenewswire.com
Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
– Petosemtamab in combination with pembrolizumab interim data presented at 2024 ASCO® demonstrated robust 67% response rate among 24 evaluable patients
Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
– Petosemtamab in combination with pembrolizumab interim data presented at 2024 ASCO® demonstrated robust 67% response rate among 24 evaluable patients
07/29 11:06 EST - zacks.com
Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Merus (MRUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Merus (MRUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
07/24 07:00 EST - globenewswire.com
Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC
Petosemtamab 1500 mg Q2W confirmed for both 2/3L phase 3 trial (LiGeR-HN2) and 1L trial (LiGeR-HN1) in r/m HNSCC following FDA feedback Petosemtamab 1500 mg Q2W confirmed for both 2/3L phase 3 trial (LiGeR-HN2) and 1L trial (LiGeR-HN1) in r/m HNSCC following FDA feedback
Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC
Petosemtamab 1500 mg Q2W confirmed for both 2/3L phase 3 trial (LiGeR-HN2) and 1L trial (LiGeR-HN1) in r/m HNSCC following FDA feedback Petosemtamab 1500 mg Q2W confirmed for both 2/3L phase 3 trial (LiGeR-HN2) and 1L trial (LiGeR-HN1) in r/m HNSCC following FDA feedback
06/03 14:30 EST - globenewswire.com
Merus' MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of a poster regarding MCLA-129 presented at the 2024 American Society of Clinical Oncology® (ASCO®) Annual Meeting taking place in Chicago May 31-June 4, 2024.
Merus' MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of a poster regarding MCLA-129 presented at the 2024 American Society of Clinical Oncology® (ASCO®) Annual Meeting taking place in Chicago May 31-June 4, 2024.
06/02 12:30 EST - globenewswire.com
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced updated interim clinical data on MCLA-145 monotherapy and in combination with pembrolizumab were presented at the 2024 American Society of Clinical Oncology® (ASCO®) Annual Meeting taking place in Chicago May 31-June 4, 2024.
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced updated interim clinical data on MCLA-145 monotherapy and in combination with pembrolizumab were presented at the 2024 American Society of Clinical Oncology® (ASCO®) Annual Meeting taking place in Chicago May 31-June 4, 2024.
05/29 21:30 EST - globenewswire.com
Merus Announces Pricing of Upsized Public Offering of Common Shares
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the pricing of an upsized underwritten public offering of 7,550,000 common shares, at a public offering price of $53.00 per share (the “Offer Shares”). Merus also granted the underwriters a 30-day option to purchase up to an additional 1,132,500 common shares (the “Option Shares” and together with the Offer Shares, the “Shares”). The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses and excluding the underwriters' option to purchase the Option Shares, are expected to be approximately $400.2 million. All of the shares in the offering are to be sold by Merus.
Merus Announces Pricing of Upsized Public Offering of Common Shares
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the pricing of an upsized underwritten public offering of 7,550,000 common shares, at a public offering price of $53.00 per share (the “Offer Shares”). Merus also granted the underwriters a 30-day option to purchase up to an additional 1,132,500 common shares (the “Option Shares” and together with the Offer Shares, the “Shares”). The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses and excluding the underwriters' option to purchase the Option Shares, are expected to be approximately $400.2 million. All of the shares in the offering are to be sold by Merus.
05/29 08:00 EST - globenewswire.com
Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 11:00 a.m. ET.
Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 11:00 a.m. ET.
05/28 16:01 EST - globenewswire.com
Merus N.V. Announces Proposed Public Offering of Common Shares
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the launch of a proposed underwritten public offering of $300,000,000 of its common shares (the “Offer Shares”). All of the common shares are being offered by Merus. In addition, Merus expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the Offer Shares (the “Option Shares” and together with the Offer Shares, the “Shares”). The offering is subject to market conditions and other closing conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Merus N.V. Announces Proposed Public Offering of Common Shares
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the launch of a proposed underwritten public offering of $300,000,000 of its common shares (the “Offer Shares”). All of the common shares are being offered by Merus. In addition, Merus expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the Offer Shares (the “Option Shares” and together with the Offer Shares, the “Shares”). The offering is subject to market conditions and other closing conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
05/28 07:00 EST - globenewswire.com
Merus' Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC
67% response rate observed among 24 evaluable patients Conference Call on Tuesday, May 28 th at 8 a.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass.
Merus' Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC
67% response rate observed among 24 evaluable patients Conference Call on Tuesday, May 28 th at 8 a.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass.
05/27 12:41 EST - zacks.com
Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data
Data from an earlier cut-off date shows that treatment with Merus' (MRUS) combination therapy achieved a 60% response rate in patients with head and neck cancer.
Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data
Data from an earlier cut-off date shows that treatment with Merus' (MRUS) combination therapy achieved a 60% response rate in patients with head and neck cancer.
05/24 13:00 EST - seekingalpha.com
Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)
Merus N.V. is experiencing significant growth and entering a higher price territory, making the risk-reward less clear. The company's bispecific antibody, petosemtamab, showed promising results in a phase 2 study for head and neck squamous cell carcinoma. Merus' other bispecific antibody, zenocutuzumab, has a high chance of approval for NRG1-positive NSCLC and pancreatic cancer, with a decision expected later in 2024.
Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)
Merus N.V. is experiencing significant growth and entering a higher price territory, making the risk-reward less clear. The company's bispecific antibody, petosemtamab, showed promising results in a phase 2 study for head and neck squamous cell carcinoma. Merus' other bispecific antibody, zenocutuzumab, has a high chance of approval for NRG1-positive NSCLC and pancreatic cancer, with a decision expected later in 2024.
05/23 17:00 EST - globenewswire.com
Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting
- 60% response rate observed among 10 evaluable patients - F avorable safety profile in 26 patients enrolled as of the abstract cutoff date , with no significant overlapping toxicities observed - Conference call on Tuesday, May 28 at 8:00 a.m. ET to discuss full ASCO® data set UTRECHT, The Netherlands and CAMBRIDGE, Mass.
Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting
- 60% response rate observed among 10 evaluable patients - F avorable safety profile in 26 patients enrolled as of the abstract cutoff date , with no significant overlapping toxicities observed - Conference call on Tuesday, May 28 at 8:00 a.m. ET to discuss full ASCO® data set UTRECHT, The Netherlands and CAMBRIDGE, Mass.
05/23 17:00 EST - globenewswire.com
Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting
MCLA-145 monotherapy and in combination with pembrolizumab rapid oral session presentation: June 2, 2024, 11:30 a.m.-1:00 p.m. CT
Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting
MCLA-145 monotherapy and in combination with pembrolizumab rapid oral session presentation: June 2, 2024, 11:30 a.m.-1:00 p.m. CT
05/13 08:00 EST - globenewswire.com
Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®) for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for petosemtamab for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed following treatment with platinum based chemotherapy and an anti-programmed cell death receptor-1 (PD-1) or anti-programmed death ligand 1 (PD-L1) antibody. This designation follows receipt of Fast Track Designation for petosemtamab for the treatment of patients with recurrent or metastatic HNSCC whose disease has progressed following treatment with platinum-based chemotherapy and an anti-programmed cell death protein 1 (anti-PD-1) antibody announced in August 2023.
Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®) for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for petosemtamab for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed following treatment with platinum based chemotherapy and an anti-programmed cell death receptor-1 (PD-1) or anti-programmed death ligand 1 (PD-L1) antibody. This designation follows receipt of Fast Track Designation for petosemtamab for the treatment of patients with recurrent or metastatic HNSCC whose disease has progressed following treatment with platinum-based chemotherapy and an anti-programmed cell death protein 1 (anti-PD-1) antibody announced in August 2023.
05/08 16:15 EST - globenewswire.com
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the first quarter and provided a business update.
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the first quarter and provided a business update.
05/06 16:05 EST - globenewswire.com
Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC
If approved, Zeno will be the first targeted therapy for NRG1+ cancer If approved, Zeno will be the first targeted therapy for NRG1+ cancer
Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC
If approved, Zeno will be the first targeted therapy for NRG1+ cancer If approved, Zeno will be the first targeted therapy for NRG1+ cancer
04/26 09:01 EST - zacks.com
Merus (MRUS) Moves 7.1% Higher: Will This Strength Last?
Merus (MRUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Merus (MRUS) Moves 7.1% Higher: Will This Strength Last?
Merus (MRUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
04/25 11:07 EST - zacks.com
Will Merus N.V. (MRUS) Report Negative Q1 Earnings?
Merus (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Merus N.V. (MRUS) Report Negative Q1 Earnings?
Merus (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.